Shattuck Labs, Inc.
NASDAQ:STTK · NASDAQ Global Select
+$0.11 today
Vol 1.22M · Avg 0.69M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:STTK · Revenue to Net Income
Key Ratios
Analysis
$1.0M of revenue converted into -$49.9M of net income for the selected period. Gross margin is 25.0% and net margin is -251.4%, showing how much revenue survives after costs and taxes. EPS is $-0.63, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M -82.5% | $5.7M +245.3% | $1.7M +154.1% | $652.0K -97.8% | $30.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $4.9M +21.1% | $4.0M -95.1% | $82.2M +5856.4% | $1.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.0M +20.9% | $827.0K +134.7% | -$2.4M +97.1% | -$81.5M -384.8% | $28.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +85.5pp | 14.5% +158.4pp | -143.9% +12363.3pp | -12507.2% -12602.6pp | 95.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $35.3M -47.5% | $67.2M -9.6% | $74.3M -10.4% | $82.9M +46.6% | $56.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.2M -9.7% | $19.1M -1.2% | $19.3M -1.9% | $19.7M +5.1% | $18.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $52.5M -35.5% | $81.4M -9.1% | $89.6M +311.2% | $21.8M -70.5% | $73.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.7M -3.7% | $3.8M -5.3% | $4.0M +31.5% | $3.1M +122.7% | $1.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$45.1M +37.0% | -$71.6M +14.0% | -$83.3M +15.8% | -$98.9M -126.8% | -$43.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -4512.1% -3260.9pp | -1251.2% +3773.3pp | -5024.5% +10139.9pp | -15164.4% -15019.2pp | -145.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$51.5M +36.1% | -$80.6M +12.4% | -$92.0M +11.0% | -$103.3M -128.3% | -$45.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -5150.8% -3742.5pp | -1408.3% +4141.3pp | -5549.6% +10298.4pp | -15848.0% -15697.2pp | -150.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.7M -47.8% | $5.2M +10.8% | $4.7M +193.3% | $1.6M +154.7% | $625.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.7M -47.7% | $5.2M +10.7% | $4.7M +236.6% | $1.4M +369.2% | $295.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$48.8M +35.3% | -$75.4M +13.6% | -$87.3M +14.4% | -$101.9M -126.7% | -$45.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -4880.9% -3562.8pp | -1318.1% +3950.3pp | -5268.4% +10367.3pp | -15635.7% -15485.9pp | -149.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$48.8M +35.3% | -$75.4M +13.6% | -$87.3M +14.4% | -$101.9M -126.7% | -$45.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -4880.9% -3562.8pp | -1318.1% +3950.3pp | -5268.4% +10367.3pp | -15635.7% -15485.9pp | -149.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +53.0% | -$1 +27.3% | -$2 +14.9% | -$2 -125.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +53.0% | -$1 +27.3% | -$2 +14.9% | -$2 -125.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $69.6M +37.1% | $50.8M +19.2% | $42.6M +0.5% | $42.4M +0.8% | $42.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $69.6M +37.1% | $50.8M +19.2% | $42.6M +0.5% | $42.4M +0.8% | $42.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
Sutro Biopharma, Inc.
NASDAQ:STRO
$277.15M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$261.61M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$238.39M
InflaRx N.V.
NASDAQ:IFRX
$130.04M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.30M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$88.56M
ImageneBio Inc
NASDAQ:IMA
$63.73M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.26M
Metagenomi, Inc. Common Stock
MGX
$45.74M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does STTK generate?
Shattuck Labs, Inc. (STTK) reported $1.00M of revenue in fiscal 2025.
Is STTK profitable?
Shattuck Labs, Inc. (STTK) reported -$48,809,000.00 of net income, with a net margin of -4880.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.